IN
Indoco Remedies Ltd (INDOCO)
₹208.30
Mkt cap
₹2,298 Cr
P/E ratio
—
P/B
2.04
Div yield
0.08%
ROE
−9.36%
ROCE
0.96%
EPS (TTM)
—
Book value
₹102
52W range
162–291
Sector
Healthcare
Price history
Previous close
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). [1]
NSE INDOCOBSE 532612
Health check
Cautious
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−28.42% from high₹208
₹162+28.43% from low₹291
Current
₹208.30
Prev close
₹209.10
Day
−0.38%
Price performance
1D
−0.38%
1W
−8.04%
1M
−22.61%
3M
−3.87%
6M
−0.58%
1Y
−26.19%
YTD
−8.10%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026NSE | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 426 | 482 | 459 | 450 | 431 | 433 | 411 | 390 | 440 | 485 | 445 | 476 | 468 | 520 | |
| Expenses | 365 | 410 | 397 | 401 | 384 | 392 | 399 | 391 | 422 | 442 | 414 | 426 | 426 | 474 | |
| Operating Profit | 61 | 71 | 63 | 49 | 48 | 40 | 12 | -1 | 18 | 43 | 32 | 50 | 41 | 46 | |
| OPM % | 14% | 15% | 14% | 11% | 11% | 9% | 2.9% | -0.2% | 4.0% | 9% | 7% | 10% | 9% | 9% | |
| Other Income | 0 | 4 | -6 | 22 | 1 | 2 | 2 | 2 | 2 | 0 | -5 | 4 | 100 | 39 | |
| Interest | 8 | 8 | 10 | 12 | 14 | 18 | 16 | 18 | 26 | 25 | 26 | 46 | 28 | 27 | |
| Depreciation | 20 | 21 | 24 | 26 | 28 | 29 | 29 | 29 | 30 | 32 | 32 | 32 | 35 | 34 | |
| Profit before tax | 34 | 46 | 23 | 33 | 7 | -5 | -31 | -46 | -37 | -14 | -31 | -25 | 78 | 24 | |
| Tax % | 29% | 24% | 31% | 33% | 74% | 107% | -8% | -9% | -1% | -32% | -6% | -5% | 16% | 20% | |
| Net Profit | 24 | 35 | 16 | 22 | 2 | -10 | -28 | -41 | -36 | -9 | -29 | -24 | 65 | 19 | |
| EPS in Rs | 2.65 | 3.81 | 1.77 | 2.46 | 0.28 | -1.04 | -2.86 | -4.38 | -3.88 | -0.86 | -3.23 | -2.34 | 7.04 | 2.11 | |
| Raw PDF | — |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202658.86%Promoter
Promoters58.86%
FIIs1.27%0.33
DIIs17.68%0.47
Public22.04%0.14
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Indoco Remedies | ₹249.01 | — | 2,298 | 0.08% | 65 | +45.56% | 468 | +6.33% | 0.96% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts46
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptJul 2025PPTJul 2025TranscriptMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025TranscriptOct 2024PPTOct 2024TranscriptJul 2024PPTJul 2024TranscriptJun 2024PPTJun 2024RECJun 2024TranscriptJan 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Acquisition 18 Sep - Indoco Remedies approved incorporation of wholly owned subsidiary Warren Lifesciences Pvt Ltd on 18 September 2026.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 18 Sep - 79th AGM voting results disclosed; shareholders approved final dividend, director reappointment, borrowing limit, and related resolutions.Shareholder Meeting / Postal Ballot-Outcome of AGM 17 SepDisclosure Under Regulation 30 Of SEBI (LODR) Regulations,2015 10 Sep - UK MHRA inspected Goa Plant I from Sept 7-9, 2026; no critical or major observations.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 10 Sep - Promoter group bought 38,930 shares on 8-9 September 2026, raising holding to 7.30%.